Market Overview

UPDATE: Canaccord Genuity Raises PT to $44 on Aegerion Pharmaceuticals on Encouraging Sales Data

Share:
Related AEGR
Mid-Day Market Update: LendingClub Slides Amid Dept. Of Justice Subpoena; Top Image Systems Shares Surge
Mid-Morning Market Update: Markets Open Lower; Home Depot Profit Tops Views

Canaccord Genuity maintained Aegerion Pharmaceuticals (NASDAQ: AEGR) with a Buy rating and raised the price target from $36.00 to $44.00.

Canaccord Genuity commented, "On the Q4 EPS call, AEGR provided metrics on the first six weeks of the Juxtapid launch in HoFH. The key takeaway was 400+ vs. 1800-targeted U.S. physicians have been REMS-trained (expected to translate into scripts 1-8 weeks post) and have written 85 new scripts globally (“vast majority” in the U.S. – Brazil and Turkey may be active on a named-patient basis). Given the strong early launch progress, we question whether guidance of 250-300 patients on drug exiting 2013 and $15M-25M in 2013 revenue is conservative."

Aegerion Pharmaceuticals closed at $36.12 on Wednesday.

Latest Ratings for AEGR

DateFirmActionFromTo
Feb 2016Bank of AmericaDowngradesNeutralUnderperform
Dec 2015Guggenheim SecuritiesUpgradesSellBuy
Nov 2015Bank of AmericaUpgradesUnderperformNeutral

View More Analyst Ratings for AEGR
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Related Articles (AEGR)

View Comments and Join the Discussion!